Product Safety Litigation: When Recall Documents Become the Evidence

Section 2064(b) requires reporting when a manufacturer, importer, distributor, or retailer obtains information reasonably supporting the conclusion that a product fails to comply with an applicable consumer product safety rule, contains a defect that could create a substantial product hazard, or creates an unreasonable risk of serious injury or death. The standard is when the company obtains information suggesting the conclusion, not when an internal investigation confirms it.

The reporting timeline is demanding, and many companies fail to meet it. When a company received consumer injury reports, warranty claims, or retailer complaints identifying a hazard, conducted an internal safety assessment, and continued selling the product without reporting to the CPSC, the gap between the date it first received relevant information and the date it eventually filed a report or initiated a recall is one of the most damaging facts in subsequent litigation. That gap is measured precisely because the reporting obligation is triggered by receipt of information, not by conclusion of an internal investigation.

Internal risk assessment documents, hazard analysis reports, and communications between product safety, legal, and executive teams during the period between first knowledge and eventual reporting are the most probative documents in a product safety case. Courts evaluating privilege claims over these communications must determine whether the documents were primarily legal in nature or primarily operational safety communications, and the crime-fraud exception may apply when communications reflect a decision to conceal a known hazard rather than to seek legal advice about disclosure. Defective product and defective products litigation in consumer product cases requires obtaining the complete CPSC file through FOIA before depositions begin, because the agency file frequently contains complaint and injury data that the company reported selectively or belatedly.

Federal preemption is a significant defense in product safety litigation, but its scope varies dramatically by product category and by whether the preemption is express or implied, and the available common law claims survive in most consumer product cases.

The CPSA at § 2075(a) expressly preempts state requirements that impose requirements or prohibitions applicable to the same aspect of a consumer product as a CPSC safety standard, where the state requirement differs from the federal standard. However, § 2075(b) expressly preserves private common law damages claims. A state safety regulation that imposes a different standard than a CPSC rule may be preempted, but the plaintiff's negligence and strict liability claims under state tort law are not preempted by CPSA safety standards. This is a fundamentally different preemption landscape from the one that applies to FDA-approved medical devices subject to premarket approval, where Riegel v. Medtronic, 552 U.S. 312 (2008), held that both express and implied preemption can block state tort claims for PMA-approved devices.

For 510(k)-cleared medical devices, the preemption analysis is less protective of the manufacturer. Medtronic v. Lohr, 518 U.S. 470 (1996), held that FDA 510(k) clearance does not preempt state tort claims in the same way PMA approval does, because 510(k) clearance is a market-entry mechanism rather than a safety determination. A plaintiff injured by a 510(k)-cleared device has a stronger path through preemption than a plaintiff injured by a PMA-approved device with the same defect. The preemption analysis must be conducted product by product and claim by claim, because the CPSA, the MVSA, and the FDCA each have different preemption provisions with different scope and different exceptions. Pharmaceutical litigation and product liability preemption analysis requires identifying the exact regulatory pathway the product traveled before any defense strategy is developed.

Industry voluntary safety standards, including those issued by ASTM International, Underwriters Laboratories, and the International Organization for Standardization, are not legally binding requirements but are highly relevant in product safety litigation. A manufacturer that certifies its product as complying with a specific ASTM standard has represented to buyers and regulators that the product meets that standard's safety requirements. Evidence that the product failed to meet the standard it was certified against is simultaneously evidence of a manufacturing defect and evidence that the manufacturer's own certification was false. Conversely, a manufacturer that complied with all applicable voluntary standards at the time of design can argue that the design was consistent with industry practice, though compliance with a voluntary standard does not automatically preclude a design defect claim if the plaintiff can show the standard itself was inadequate to address the known risk. Mass torts and class action litigation cases against manufacturers often turn on whether the applicable voluntary standard was adequate, because a standard-setting process influenced by the industry it regulated may not reflect an independent assessment of what level of safety was feasible.

The CPSC's National Electronic Injury Surveillance System and SaferProducts.gov database provide independent sources of consumer injury data that exist outside the defendant's control, but each has evidentiary limitations that must be understood before relying on them in litigation.

NEISS is a statistically valid injury surveillance system based on a nationally representative probability sample of hospital emergency departments. It captures injury estimates involving consumer products by product code, injury type, and disposition. NEISS data can help identify injury patterns and support expert analysis of whether a product category is associated with recurring injury reports, but it does not prove defect or causation for a specific product or plaintiff by itself. An epidemiological or biostatistical expert can use NEISS estimates as one input into a broader analysis, but the data's product code level of granularity means it tracks injury categories rather than specific products, and that limitation must be disclosed when the data is offered through an expert.

SaferProducts.gov contains consumer incident reports filed directly with the CPSC, many of which identify specific product models and describe specific incident types. These reports can help identify prior similar incidents and notice leads that guide further investigation, but plaintiffs still need to establish substantial similarity, authentication, and admissibility before using specific reports as trial evidence. Consumer-submitted reports are unverified, may contain hearsay within hearsay, and are subject to Rule 403 challenges if individual reports contain unreliable or inflammatory descriptions. The strongest use of SaferProducts.gov in litigation is as a discovery lead and corroboration tool alongside the defendant's own internal incident tracking records, not as a standalone evidentiary foundation.

Product safety litigation focuses on the intersection of federal regulatory obligations and civil tort claims, centering on what the manufacturer knew about a product's hazard, when they knew it, and what federal law required them to do that they failed to do. Standard product liability establishes the defect, the causation, and the injury. Product safety litigation adds the regulatory dimension: whether the company complied with mandatory reporting obligations under the CPSA, the MVSA, or FDA's medical device reporting rules, whether a recall was timely, and what the company's internal safety assessment process revealed before regulatory action was required. The regulatory record provides evidence of prior knowledge and delayed action that supplements what the plaintiff can develop through private discovery alone.

A recall itself is generally excluded as a subsequent remedial measure under Federal Rule of Evidence 407, but the documents that preceded and accompanied the recall are not subject to that exclusion. The Corrective Action Plan submitted to the CPSC, the internal hazard analysis that preceded it, and the communications between safety, legal, and executive teams during the period between first knowledge and recall initiation are all subject to civil discovery. Admissibility of those documents depends on the purpose offered, hearsay treatment, and Rule 403 balancing, but courts that admit them as evidence of hazard notice rather than as proof of subsequent remediation can give the plaintiff direct access to the manufacturer's own hazard assessment. A company that acted promptly after identifying the hazard has a stronger litigation position than one whose internal record shows delayed action or avoidance of a public recall.

The CPSC covers most consumer products and maintains SaferProducts.gov consumer incident reports and NEISS injury surveillance data that are publicly accessible. NHTSA covers motor vehicles and equipment and maintains Early Warning Reporting data, including consumer complaints, warranty claims, field reports, and death and injury reports, submitted by manufacturers. The FDA covers medical devices, drugs, and biologics and maintains the MAUDE adverse event database for medical devices and FAERS for pharmaceutical products. All three agencies' records are obtainable through FOIA and provide an independent source of prior knowledge evidence that supplements private discovery from the manufacturer.

Federal preemption varies significantly by product category. The CPSA expressly preserves private common law damages claims even when it preempts conflicting state safety regulations, so most consumer product claims survive preemption challenges. Medical device claims face the most complex preemption landscape: PMA-approved devices receive strong preemption protection under Riegel v. Medtronic, while 510(k)-cleared devices receive weaker preemption protection under Medtronic v. Lohr. Drug product claims generally survive preemption for brand-name drugs under Wyeth v. Levine but face greater barriers for generic drugs. The preemption analysis must be conducted for the specific product, its exact regulatory pathway, and the specific claim asserted, because no single answer applies across product categories.